YH 12852

Drug Profile

YH 12852

Alternative Names: YH12852

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyspepsia
  • Phase I/II Constipation
  • No development reported Irritable bowel syndrome

Most Recent Events

  • 01 Sep 2016 Yuhan Corporation completes a phase I/IIa trial for Constipation in South Korea (NCT02538367)
  • 03 Jan 2016 Yuhan Corporation suspends a phase II trial in Dyspepsia in South Korea (NCT02567578)
  • 01 Oct 2015 Phase-II clinical trials in Dyspepsia in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top